MONROL
10.5.2022 06:02:14 CEST | Business Wire | Press release
Eczacıbaşı-Monrol Nuclear Products Co. (Monrol) has today announced that the first patient has been dosed in the ‘STARLITE 2’ Phase II study of Telix Pharmaceuticals Limited (Telix) investigational renal cancer therapy product, TLX250 (177 Lu-DOTA-girentuximab), at Memorial Sloan Kettering Cancer Center (MSK) in New York. Monrol supplied Lutetium (Lu-177 n.c.a) to Telix Pharmaceuticals to manufacture clinical doses of TLX250 for STARLITE 2 Phase II study. This collaboration may offer significant opportunities for clear cell renal cell carcinoma (ccRCC) patients in the future.
The STARLITE 2 Phase II study (NCT05239533 ) will assess the efficacy of TLX250 targeted radiation in combination with the anti-PD-11 immunotherapy Opdivo®2 (nivolumab) for ccRCC, the most common and aggressive form of kidney cancer. The primary endpoint is to determine the safety and efficacy of combination therapy with TLX250 as assessed by the tumours responding to the Telix therapy versus the current standard of care alone. TLX250 targets carbonic anhydrase IX (CA9),3 a protein that is highly expressed in patients that are likely to demonstrate a more limited response to cancer immunotherapy.4 The concept is that low doses of targeted radiation can potentially overcome immune resistance – or “immune prime” a tumour and therefore make it more responsive to cancer immunotherapy. Telix’s investigational companion imaging agent TLX250-CDx (89 Zr-DFO-girentuximab) will also be used in the study to image CA9 expression.
Clinical doses of Telix’s investigational renal cancer companion imaging agent TLX250-CDx (89 Zr-DFO-girentuximab) is also produced by Eczacıbası Monrol in its Istanbul facility for the Phase III ZIRCON clinical trial.
ZIRCON Phase III study (“Zirconium Imaging in Renal Cancer Oncology”) is an international multi-centre study at 34 sites in Europe, Australia, Turkey, Canada, and the United States. The study enrolled 30 patients in Turkey. The objective of the ZIRCON trial is to evaluate the sensitivity and specificity of PET/CT imaging with TLX250-CDx to non-invasively detect ccRCC in patients with indeterminate renal masses in comparison with surgical resection (histology), as the standard of truth.
Monrol is a company developing, manufacturing, and distributing world-class radiopharmaceutical products, radioisotopes to improve quality of life of cancer patients globally and one of the few producers of Lutetium-177 n.c.a, having uninterrupted worldwide supply capabilities. Monrol Lu-177 n.c.a production process is an exclusive processing technology having cleaner and safer production method with stable isotope enrichment capability.
"Lu-177 n.c.a contributes to our mission to improve quality of life of cancer patients globally. Our new GMP certified facility exclusively designed for theranostic R&D and production with cutting edge technology will enable us to maximize supply of high-quality Lutetium worldwide. We are committed to working closely with Telix to potentially bring new therapeutic radiopharmaceutical agents into market soon to improve patients’ lives having life threatening diseases” said Monrol General Manager Aydin Kucuk”.
Telix Chief Medical Officer, Dr. Colin Hayward noted, “The integration of precision nuclear medicine and medical oncology is underway and Telix is at the forefront of this movement to develop personalised products and patient-friendly regimens. We wish to express our gratitude to Dr. Darren Feldman and his clinical team, as well as the patients who will contribute to this ground-breaking study STARLITE 2”.
Disclosure: MSK has institutional financial interests related to Telix.
About Lutetium-177 n.c.a
Lutetium-177 n.c.a is a radioisotope of choice for targeted radionuclide therapy. Lu-177 n.c.a production process enables treatment options that have the potential to improve treatment outcomes for certain cancer patients today. Unique properties of Lutetium-177 n.c.a makes it a theranostically desirable radioisotope for peptide receptor radionuclide therapy (PRRT) to treat certain cancers like Neuro Endocrine Tumors (NET), Prostate cancer and many other clinical development programs are ongoing for other cancers like ccRCC.
In line with the company mission to create hope for a better life for cancer patients, Monrol is establishing strategic partnerships with multinational pharmaceutical companies and constructing a new production facility compliant with FDA 21 CFR Part 211 quality standards which will have an annual production capacity of 60 thousand doses. With its location close to Istanbul, a major transportation hub, the new facility will benefit from a worldwide logistics network and agreements with cargo services to 320 destinations worldwide.
About TLX250
TLX250 (177 Lu-DOTA-girentuximab) is an antibody-based therapeutic platform that targets carbonic anhydrase IX (CA9), a cell surface protein that is highly expressed in several human cancers including ccRCC. High CA9 tumour expression is generally correlated with poor prognosis.
About TLX250-CDx
TLX250-CDx (89Zr-girentuximab) is being developed by Telix for the purpose of determining whether “indeterminate renal masses”, typically identified based on CT or MRI imaging, are either clear cell renal cell cancer (ccRCC) or non-ccRCC, using Positron Emission Tomography (PET) imaging. Girentuximab is a monoclonal antibody that targets carbonic anhydrase IX (CAIX), a cell surface target that is highly expressed in several human cancers including renal, lung and oesophageal cancers. In July 2020, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy (BT) designation for TLX250-CDx, reflecting the significant unmet clinical need to improve the diagnosis and staging of ccRCC, the most common and aggressive form of kidney cancer. Telix’s companion investigational diagnostic imaging agent TLX250-CDx (89 Zr-DFO-girentuximab) is the subject of a global Phase III trial recruiting (ZIRCON trial, NCT03849118 ).
About Monrol
Monrol is one of the world’s largest nuclear medicine companies leading innovation for the development and manufacturing of GMP grade radioisotopes and radiopharmaceuticals having headquarters in Istanbul. Monrol is distributing its world-class radiopharmaceutical products portfolio with excellence in global markets. Monrol is a CDMO, providing early development support to its customers as well as offering fully integrated services for today’s nimble, lean, virtual companies effectively taking new product concepts into clinical trials, demonstrating proof of concept and going into first-in-human studies. Monrol is committed to transform and improve patient journey in cancer treatment with its radiopharmaceutical products portfolio distributing to more than 50 countries around the globe. To learn more, visit www.monrol.com and LinkedIn .
About Telix Pharmaceuticals Limited
Telix is a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan, Switzerland, and the United States. Telix is developing a portfolio of clinical-stage products that address significant unmet medical need in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information visit www.telixpharma.com and follow Telix on Twitter (@TelixPharma) and LinkedIn .
Telix’s lead product, gallium-68 (68 Ga) gozetotide (also known as 68 Ga PSMA-11) injection for prostate cancer imaging, has been approved by the U.S. Food and Drug Administration (FDA),5 and by the Australian Therapeutic Goods Administration (TGA).6 Telix is also progressing marketing authorisation applications for this investigational candidate in Europe7 and Canada.8
1
Programmed cell death protein 1.
2
Opdivo is a registered trade mark of Bristol Myers Squibb.
3
Carbonic anhydrase IX.
4
Giatromanolaki et al. British Journal of Cancer
. 2020.
5
ASX disclosure 20 December 2021.
6
ASX disclosure 2 November 2021.
7
ASX disclosure 10 December 2021.
8
ASX disclosure 16 December 2020.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220505005820/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
World Employment Confederation’s 59th Annual Conference to Address Critical Global Labour Market Concerns8.5.2026 07:12:00 CEST | Press release
Senior leaders from policy, business and international institutions are set to discuss critical labour market concerns at the World Employment Confederation’s Annual Conference, during an era of global transformation and disruption never-before-seen. Taking place on 12-13 May in Toronto and entitled ‘Grow With Talent’, this year’s World Employment Conference – co-organised with ACSESS – arrives at a time of profound economic uncertainty. This gathering of leaders and experts will help define the path forward for the global labour market and set the stage for discussions at the 114th Session of the International Labour Conference (ILC) in June. Bettina Schaller, President of World Employment Confederation (WEC) says: “The question at the heart of this year’s World Employment Conference is: how will we mobilise the world’s talent to drive growth in an era of disruption?At a time of accelerating AI adoption, rapid demographic change and an uncertain global economic outlook, pressure on la
Esentia Announces Successful Pricing of 6.125% Senior Notes Due 2033 and 6.500% Senior Notes Due 20388.5.2026 03:24:00 CEST | Press release
Esentia Energy Development, S.A.B. de C.V. (“ESENTIA” or the “Company”), today announced the pricing of U.S.$1,000,000,000.00 aggregate principal amount of its 6.125% Senior Notes due 2033 (the “2033 Notes”) and U.S$1,000,000,000.00 aggregate principal amount of its 6.500% Senior Notes due 2038 (the “2038 Notes” and, together with the 2033 Notes, the “Notes”) to be issued by the Company in a private offering to qualified institutional buyers in accordance with Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), and outside the United States to non-U.S. persons in accordance with Regulation S under the Securities Act. The 2033 Notes will be issued at a price of 99.517%, and the 2038 Notes will be issued at a price of 98.444%. The 2033 Notes mature on July 30, 2033, and the 2038 Notes mature on July 30, 2038, and will be fully and unconditionally guaranteed by certain of the Company's subsidiaries. The settlement of the Notes is expected to take place on May 14
83% of Restaurants Are Invisible in AI Search: New Uberall Report Reveals the Discovery Gap Reshaping the Quick Service Restaurant Industry7.5.2026 19:35:00 CEST | Press release
Industry-first benchmark study analyzes how ChatGPT, Gemini, Perplexity, Copilot and Google AI Overviews recommend restaurants Uberall, the global leader in location marketing technology, today released Fast Food, Faster Discovery: The 2026 GEO Playbook for Multi-Location QSRs — the industry’s first benchmark report measuring how AI assistants recommend restaurants and how multi-location QSR (Quick-Service Restaurant) brands can adapt their local marketing strategies for AI-mediated search. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507962493/en/ Fast Food, Faster Discovery: Why AI Is the New Drive-Thru The report draws on Uberall’s proprietary GEO Studio benchmark data and aggregated performance metrics from its global QSR customer base. Its central finding: as consumer restaurant discovery rapidly shifts from traditional search to AI assistants, the majority of QSR locations are effectively absent from AI-generated
Department of Health - Abu Dhabi and ŌURA Partner to Advance Preventive Health in Abu Dhabi7.5.2026 18:57:00 CEST | Press release
Initially focused on women’s health, the partnership will unite Department of Health - Abu Dhabi’s longitudinal health data with ŌURA’s real-time insights, underpinned by a rigorous joint data governance framework Department of Health—Abu Dhabi (DoH) and ŌURA, maker of the world’s leading smart ring, Oura Ring, today announced a joint research programme to study how continuous wearable data can advance preventive health. The collaboration marks the beginning of a long-term partnership to advance Abu Dhabi’s prevention-first, data-driven healthcare agenda, and will initially focus on women’s health and cardiometabolic risk. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507073495/en/ HE Mansoor Al Mansoori (Left) and Tom Hale (Right) The collaboration builds on Abu Dhabi’s advanced public health infrastructure and longitudinal health data assets, integrating them with ŌURA’s real-time, continuous insights across key health
Rave Sues Apple in Five Countries Over App Store Removal7.5.2026 17:03:00 CEST | Press release
Alleges Antitrust Violations in U.S., Canada, Brazil, the Netherlands and Russia to Restore Access for Users and Defend Fair Competition for App DevelopersAlleges Apple Acted to Stop Rave from Competing with Apple’s Own Co-Viewing AppRave Launches Proprietary, AI-enabled Moderation System, a-eye.com, to Protect Users from Explicit Content Rave Inc. (“Rave” or the “Company”), the developer and operator of the Rave app, a cross-platform co-viewing “super app” with more than 225 million downloads, today announced that it has filed antitrust lawsuits against Apple in five countries: the United States, Canada, Brazil, the Netherlands and Russia. The lawsuits challenge Apple’s unilateral and anticompetitive decision to remove Rave from its App Store, thereby distorting competition, reducing consumer choice in co-viewing functionalities and increasing the costs to users of switching between iPhone and competing smartphone devices. Rave operates a social entertainment app that allows users in
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom